Antimetastatic efficacy of niosomal pentoxifylline and its combination with activated macrophages in murine B16F10 melanoma model

Cancer Biotherapy and Radiopharmaceuticals

Volumn 15, Issue 6, 2000, Pages 605-615

  Gaikwad, S Y ^a   Jagtap, A G ^a   Ingle, A D ^b   Ra, S G A ^b   Gude, R P ^b  

^a BOMBAY COLLEGE OF PHARMACY   (India)

^b CANCER RESEARCH INSTITUTE   (India)

Author keywords

Activated macrophages; B16F10; Melanoma; Metastasis; Muramyl dipeptide; Niosomes; Pentoxifylline

Indexed keywords

MURAMYL DIPEPTIDE DERIVATIVE; NIOSOME; PENTOXIFYLLINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; DRUG ACCUMULATION; DRUG RELEASE; FEMALE; MACROPHAGE ACTIVATION; MALE; MELANOMA; METASTASIS; METASTASIS INHIBITION; MICROSCOPY; MOUSE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL;

EID: 0034525414     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2000.15.605     Document Type: Article

References (24)

1. Therapeutic agents for the treatment of established metastasis and inhibitors of metastatic spread: Preclinical and clinical progress
2. Niosomes as drug carriers
3. Efficiency of liposomes containing a lipophilic muramyl dipeptide for activating the tumoricidal properties of alveolar macrophages in vivo
4. Activation of tumoricidal properties in mouse macrophages by lymphokines encapsulated in liposomes
5. Involvement of macrophages in eradication of established metastases following intravenous injection of liposomes containing macrophage activators
6. Targeting of immunomodulators to mononuclear phagocytes for therapy of cancer
7. Inhibition of lung homing or B16F10 by Pentoxifylline a microfilament depolymerizing agent
8. Antiangiogenic and antimetastatic effect of pentoxifyl-line on B16F10 melanoma
9. Studies on the mechanisms responsible for inhibition of experimental metastasis of B16-F10 murine melanoma by Pentoxifylline
10. Selection of successive tumor lines for metastasis
11. The preparation and properties of niosomes non-ionic surfactant vesicles
12. The distribution of doxorubicin in mice following administration of niosomes
13. Pharmacokinetic evaluation of surfactant vesicles-entrapped Methotrexate in tumor bearing mice
14. Formulation and in vitro evaluation of Vincristine encapsulated niosomes
15. Vesicular systems (niosomes and liposomes) for delivery of Sodium stilbogluconate in experimental murine visceral leishmaniasis
16. Niosomes for oral delivery of peptide drugs
17. Procedure for preparation of liposomes with large internal aqueous phase and high capture by reverse phase evaporation
18. Biological behavior of malignant melanoma cells correlated to their survival in vivo
19. Distinct lung colonizing and lung metastasizing cell populations in B16 mouse melanoma
20. Actin depolymerization and inhibition of capping induced by Pentoxifylline in human lymphocytes and neutrophils
21. Eradication of spontaneous metastases and activation of alveolar macrophages by intravenous injection of liposomes containing muramyl dipeptide
22. Pentoxifylline prevents Concanavaline A-induced hepatitis by reducing tumor necrosis factor-α levels and inhibiting adhesion of T-lymphocytes to extracellular matrix